Sale!

Solid Tumor Combo1 EGFR ALK1 ROS1 MET PDL1 Test

Original price was: $1,250.Current price is: $938.

-25%

The Solid Tumor Combo1 EGFR ALK1 ROS1 MET PDL1 Test is a comprehensive genetic analysis that detects key biomarkers in solid tumors to guide personalized cancer treatment. This advanced diagnostic panel examines EGFR, ALK1, ROS1, MET, and PDL1 genetic mutations using sophisticated methods including FISH, Sanger Sequencing, and IHC. The test helps oncologists determine the most effective targeted therapies and immunotherapy options for patients with various solid tumors. Results are typically available within 5-7 days from tumor tissue samples. This test is essential for patients seeking precision medicine approaches to cancer care. The discounted price is $938 USD, providing significant savings from the regular $1250 USD cost.

Clinically Validated & Lab Certified

  • ISO-Accredited Laboratory, Ensuring Highest Standards
  • Trusted by Hospitals & Patients —Accredited Testing with Results
  • Direct Healthcare Provider Support + Comprehensive Reporting
Guaranteed Safe Checkout

Solid Tumor Combo1 EGFR ALK1 ROS1 MET PDL1 Test

Comprehensive Cancer Genetic Analysis for Personalized Treatment

The Solid Tumor Combo1 EGFR ALK1 ROS1 MET PDL1 Test represents a cutting-edge approach to cancer diagnostics, providing comprehensive genetic profiling of key biomarkers that drive tumor growth and treatment response. This advanced panel combines multiple testing methodologies to deliver a complete picture of your tumor’s genetic landscape, enabling oncologists to develop highly personalized treatment strategies.

What This Test Measures and Detects

This comprehensive genetic panel analyzes five critical biomarkers that play essential roles in cancer development and treatment response:

  • EGFR (Epidermal Growth Factor Receptor): Mutations in EGFR can indicate responsiveness to targeted therapies like tyrosine kinase inhibitors
  • ALK1 (Anaplastic Lymphoma Kinase)
  • ROS1: Gene fusions involving ROS1 can predict response to targeted treatments in various solid tumors
  • MET: Amplifications and mutations in MET can influence tumor growth and metastatic potential
  • PDL1 (Programmed Death-Ligand 1): Expression levels help determine eligibility for immunotherapy treatments

Who Should Consider This Test

This comprehensive genetic analysis is recommended for patients with:

  • Newly diagnosed solid tumors requiring treatment planning
  • Advanced or metastatic cancers where targeted therapy options are being considered
  • Resistance to current cancer treatments
  • Recurrent cancers requiring new treatment approaches
  • Non-small cell lung cancer, breast cancer, colorectal cancer, and other solid malignancies
  • Patients seeking precision medicine approaches to cancer care

Clinical Benefits of Genetic Testing

Undergoing the Solid Tumor Combo1 EGFR ALK1 ROS1 MET PDL1 Test provides numerous advantages:

  • Personalized Treatment Selection: Identifies the most effective targeted therapies based on your tumor’s genetic profile
  • Immunotherapy Eligibility: Determines if you’re a candidate for checkpoint inhibitor treatments
  • Avoid Unnecessary Treatments: Prevents administration of ineffective therapies and their associated side effects
  • Improved Outcomes: Increases the likelihood of treatment success through precision medicine
  • Comprehensive Analysis: Multiple biomarkers analyzed simultaneously for complete genetic assessment
  • Fast Results: Turnaround time of 5-7 days enables timely treatment decisions

Understanding Your Test Results

Your test results will provide detailed information about the genetic mutations and biomarkers detected in your tumor sample:

  • Positive Results: Indicate the presence of specific genetic alterations that may make you eligible for targeted therapies or immunotherapies
  • Negative Results: Show the absence of tested biomarkers, helping to rule out certain treatment options
  • Variant Interpretation: Results include clinical significance assessment of detected mutations
  • Treatment Recommendations: Your oncologist will use these results to develop your personalized treatment plan
  • Follow-up Testing: Additional genetic testing may be recommended based on initial findings

Test Details and Pricing

Test Component Details
Test Name Solid Tumor Combo1 EGFR ALK1 ROS1 MET PDL1
Regular Price $1250 USD
Discount Price $938 USD
Turnaround Time 5-7 days
Sample Type Tumor tissue (Paraffin embedded tissue blocks)
Testing Methods FISH, Sanger Sequencing, IHC
Specialty Oncology Genetics

Pre-Test Requirements

This test requires a Doctor’s prescription for most cases. Prescription requirements do not apply to surgery and pregnancy cases or individuals planning to travel abroad. Our team will guide you through the sample collection and submission process to ensure proper handling of your tumor tissue sample.

Nationwide Availability

We have diagnostic centers conveniently located across the United States, including major metropolitan areas such as New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, and San Jose. Our network ensures accessible testing services regardless of your location.

Take Control of Your Cancer Treatment Today

Don’t leave your cancer treatment to chance. The Solid Tumor Combo1 EGFR ALK1 ROS1 MET PDL1 Test provides the genetic insights needed to make informed treatment decisions. Our experienced oncology specialists are ready to help you navigate your cancer journey with precision and confidence.

Call or WhatsApp us today at +1(267) 388-9828 to schedule your comprehensive genetic analysis and take the first step toward personalized cancer care.